|Bid||0.00 x 800|
|Ask||0.00 x 1400|
|Day's Range||20.87 - 22.70|
|52 Week Range||3.67 - 38.50|
|Beta (5Y Monthly)||3.92|
|PE Ratio (TTM)||N/A|
|Earnings Date||Jul 26, 2021 - Jul 30, 2021|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||38.00|
Seres Therapeutics, Inc., (Nasdaq: MCRB), today announced that management will participate in a panel discussion at the RBC Capital Markets 2021 Global Healthcare Conference on Tuesday, May 18 at 4:15 p.m. ET.
Seres Therapeutics, Inc. (Nasdaq: MCRB), a leading microbiome therapeutics company, today announced that it will present recent research findings from its microbiome drug development portfolio at Digestive Disease Week® (DDW), which is taking place virtually from May 21-23, 2021. With two oral presentations and two posters of distinction, Seres will demonstrate the potential of microbiome-based therapies for patients with serious diseases like recurrent Clostridioides difficile infection (CDI) and ulcerative colitis (UC).
Today is shaping up negative for Seres Therapeutics, Inc. ( NASDAQ:MCRB ) shareholders, with the analysts delivering a...